News|Videos|November 18, 2026

Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO

Fact checked by: Patrick Campbell

Timothy Craig, DO, outlines stepwise CSU care, from antihistamine updosing to omalizumab, dupilumab, and the oral BTK inhibitor remibrutinib.

Treatment for chronic spontaneous urticaria (CSU) refractory to second-generation antihistamines now includes 3 targeted options with distinct mechanisms, according to Timothy Craig, DO, professor of medicine and pediatrics and chief of the section of allergy, asthma, and immunology at Penn State College of Medicine. In an interview, Craig outlined his stepwise approach, from antihistamine updosing through omalizumab (Xolair), dupilumab (Dupixent), and the oral Bruton tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido).

Looking for materials to share with patients?

NewBeauty, a sister brand of HCPLive, offers consumer-friendly coverage of chronic spontaneous urticaria and other chronic skin conditions, including atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, and alopecia.

The FDA approved remibrutinib on September 30, 2025, for adults with CSU who remain symptomatic despite H1 antihistamine treatment, based on the phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials.1 An indirect analysis has since suggested omalizumab and remibrutinib produce similar early gains in CSU.2 Craig noted most CSU is now considered autoimmune rather than allergic, driven by antibodies against IgE or the mast cell.

Craig begins with a once-daily second-generation antihistamine, such as cetirizine or fexofenadine, and escalates per guidelines to 2 tablets twice daily for a few weeks before moving on. He defers laboratory workup, including complete blood count, chemistry panel, C-reactive protein, erythrocyte sedimentation rate, thyroid-stimulating hormone, and thyroid antibodies, until patients fail updosing, as results are almost always normal. His treatment goal is complete absence of hives with no interference in quality of life, and sleep disturbance is a common reason patients seek care.

Among advanced therapies, omalizumab binds IgE to reduce mast cell activation, dupilumab lowers IgE and blocks other cytokines, and remibrutinib inhibits BTK to reduce histamine release. Craig described all 3 as effective, with remibrutinib and omalizumab offering rapid onset, often within days to weeks, while dupilumab works more slowly. Omalizumab retains advantages in its long history of use in pregnancy and its capacity for updosing to as high as 600 mg every 2 weeks.

"There's a small risk of bleeding with remibrutinib. But you know, that's usually when I say bleeding, it's usually just blood marks on the lower extremities under the skin. So all three are tolerated well. They all work well. You know, again, I usually go to either remibrutinib or omalizumab as my first choice and only Dupixent as the last," Craig said.

Cyclosporine remains the final option for patients uncontrolled on all 3 agents. Once disease is controlled, Craig keeps patients on at least 1 daily antihistamine alongside advanced therapy and waits roughly 3 months before tapering, since early discontinuation often leads to flares.

References
  1. Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). News release. Novartis. September 30, 2025. Accessed November 18, 2026. https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu
  2. Omalizumab, remibrutinib show similar early CSU gains in indirect analysis. HCPLive. November 13, 2026. https://www.hcplive.com/view/omalizumab-remibrutinib-show-similar-early-csu-gains-indirect-analysis

Related to this article